Expression of chromosome 21-localized genes in acute myeloid leukemia: Differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin

Blood

Volumn 94, Issue 4, 1999, Pages 1393-1400

  Taub, Jeffrey W ^a   Huang, Xi ^b   Matherly, Larry H ^b   Stout, Mark L ^b   Buck, Steven A ^b   Massey, Gita V ^b   Becton, David L ^b   Chang, Myron N ^b   Weinstein, Howard J ^b   Ravindranath, Yaddanapudi ^b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATHIONINE BETA SYNTHASE; CYTARABINE; DAUNORUBICIN; SUPEROXIDE DISMUTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHEMOTHERAPY; CHROMOSOME 21; CLINICAL ARTICLE; DISEASE ASSOCIATION; DOWN SYNDROME; DRUG MECHANISM; DRUG SENSITIVITY; GENE EXPRESSION; GENE LOCATION; HUMAN; HUMAN CELL; INFANT; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 21; CYTARABINE; DAUNORUBICIN; DOWN SYNDROME; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID; LEUKOCYTES; TUMOR CELLS, CULTURED;

EID: 0033566994     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 48:6, 1998
2. Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S, Gold S, Barnard DR, DeSwarte J, Dusenbery K, Kalousek D, Arthur DC, Lange BJ: Timed-sequential therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 87:4979, 1996
3. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, Wheatley K: Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial. Lancet 351:700, 1998
4. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J, Carroll A, Inoue S, Camilla B, Weinstein HJ: Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 334:1428, 1996
5. Taub JW, Ravindranath Y: Treatment of childhood acute myeloid leukaemia. Baillieres Clin Haematol 9:129, 1996
6. Creutzig U, Harbott J, Sperling C, Ritter J, Zimmermann M, Loffler H, Riehm H, Schellong G, Ludwig WD: Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of study AML-BFM-87. Blood 86:3097, 1995
7. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322, 1998
8. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, Chauvenet A, Alvarado CS, Dubowy R, Ritchey AK, Land V, Steuber CP, Weinstein H: Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: Experience on Pediatric Oncology Group AML study 8498. Blood 80:2210, 1992
9. Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley JD, Howells WB, Gold S, Sanders J, Neudorf S, Smith FO, Woods WG: Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 91:608, 1998
10. Slordahl SH, Gustafsson G, Jonmundsson G, Mellander L, Siimes MA, Yssing M, Lie SO: Down's syndrome (DS) and acute myelogenous leukemia (AML). A population based study in the five Nordic countries. Med Ped Oncol 20:373, 1992 (abstr)
11. Kojima S, Kato K, Matsuyama T, Yoshikawa T, Horibe K: Favorable treatment outcome in children with acute myeloid leukemia and Down syndrome. Blood 81:3164, 1993 (letter)
12. Zipursky A, Thorner P, De Harven E, Christensen H, Doyle J: Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res 18:163, 1994
13. Creutzig U, Ritter J, Vormoor J, Ludwig WD, Niemeyer C, Reinisch I, Stollmann-Gibbels B, Zimmermann M, Harbott J: Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM study group. Leukemia 10:1677, 1996
14. Taub JW, Matherly LH, Stout ML, Buck SA, Gurney JG, Ravindranath Y: Enhanced metabolism of 1-β-D-arabinofuranosylcytosine in Down syndrome cells: A contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 87:3395, 1996
15. Kruger WD, Cox DR: A yeast system for expression of human cystathionine β-synthase: Structural and functional conservation of the human and yeast genes. Proc Natl Acad Sci USA 91:6614, 1994
16. Lieman-Hurwitz J, Dafni N, Lavie V, Groner Y: Human cytoplasmic superoxide dismutase cDNA clone: A probe for studying the molecular biology of Down syndrome. Proc Natl Acad Sci USA 79:2808, 1982
17. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156, 1987
18. Forrest GL, Akman S, Doroshow J, Rivera H, Kaplan WD: Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity. Mol Pharmacol 40:502, 1991
19. Wong SC, Proefke SA, Bhushan A, Matherly LH: Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective chinese hamster ovary cells. J Biol Chem 270:17468, 1995
20. Chottiner EG, Shewach DS, Datta NS, Ashcraft E, Gribbin D, Ginsburg D, Fox IH, Mitchell BS: Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci USA 88:1531, 1991
21. Horikoshi T, Danenberg KD, Stadlbauer T, Voklenandt M, Shea LC, Aigner K, Gustavsson B, Leichman L, Frösing R, Ray M, Gibson NW, Spears CP, Danenberg PV: Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 52:108, 1992
22. Candide C, de Blois MC, Mazière C, Mazière JC, Polonovski J, Lejeune J: Méthylation des phospholipides dans les fibroblastes de patients atteints de trisomie 21. Ann Genet 30:213, 1987
23. Reglan B, Gottfries CG: Slowed synthesis of DNA and methionine is a pathogenetic mechanism common to dementia in Down's syndrome, AIDS and Alzheimer's disease? Med Hypoth 38:11, 1992
24. Rakasz E, Sugar J, Csuka O: Modulation of cytosine arabinosideinduced proliferation inhibition by exogenous adenosylmethionine. Cancer Chemother Pharmacol 28:484, 1991
25. Huang X, Stout ML, Buck SA, Ravindranath Y, Matherly LH, Taub JW: Cystathionine-β-synthase cDNA transfection alters the sensitivity of CCRF-CEM leukemia cells to cytosine arabinoside: A model of Down syndrome and leukemia. Proc Am Assoc Cancer Res 39:3181a, 1998 (abstr)
26. Hu ZB, Yang GS, Li M, Miyamoto N, Minden MD, McCulloch EA: Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: Involvement of free radicals. Leukemia 9:789, 1995
27. Dor RT, Von Hoff DD: Cancer Chemotherapy Handbook. Norwalk, CT, Appleton & Lange, 1994
28. Kedziora J, Bartosz G: Down's syndrome: A pathology involving the lack of balance of reactive oxygen species. Free Rad Biol Med 4:317, 1988
29. Peled-Kamar M, Lotem J, Okon E, Sachs L, Groner Y: Thymic abnormalities and enhanced apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing Cu/Zn-superoxide dismutase: Implications for Down syndrome. EMBO J 14:4985, 1995
30. Busciglio J, Yankner BA: Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378:776, 1995
31. de Haan JB, Wolvetang EJ, Cristiano F, Iannello R, Bladier C, Kelner MJ, Kola I: Reactive oxygen species and their contribution to pathology in Down syndrome. Adv Pharmacol 38:379, 1997
32. Watson MS, Carroll AJ, Shuster JJ, Steuber CP, Borowtiz MJ, Behm FG, Pullen DJ, Land VJ: Trisomy 21 in childhood acute lymphoblastic leukemia: A Pediatric Oncology Group study (8602). Blood 82:3098, 1993
33. Whitehead VM, Vuchich MJ, Lauer SJ, Mahoney D, Carroll AJ, Shuster JJ, Esseltine DW, Payment C, Look AT, Akabutu J, Bowen T, Taylor LD, Camitta B, Pullen DJ: Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group study. Blood 80:1316, 1992
34. Zhang L, Taub JW, Williamson M, Wong SC, Hukku B, Pullen J, Ravindranath Y, Matherly LH: Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: Relationship to immunophenotype and ploidy. Clin Cancer Res 4:2169, 1998
35. Cortes JE, Kantarjian H, O'Brien S, Keating M, Pierce S, Freireich EJ, Estey E: Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. Leukemia 9:115, 1995
36. Kempski HM, Chessells JM Reeves BR: Deletions of chromosome 21 restricted to the leukemic cells of children with Down syndrome and leukemia. Leukemia 11:1973, 1997
37. Holtzman DM, Epstein CJ: The molecular genetics of Down syndrome. Mol Genet Med 2:105, 1992
38. Scott HS, Papasavvas M-P, Rossier C, Michaud J, Chrast R, Velculescu VE, Dahoun S, Barras C, Buell G, Feger G, Antonarakis SE: A global comparison of gene expression patterns between Down syndrome and normal cells by Serial Analysis of Gene Expression (SAGE). Am J Human Genet 63:113, 1998 (abstr, suppl 1)
39. Ives JH, Dagna-Bricarelli F, Basso G, Antonarakis SE, Jee R, Cotter F, Nizetic D: Increased levels of a chromosome 21-encoded tumor invasion and metastasis factor (TIAM 1 ) mRNA in bone marrow of Down syndrome children during the acute phase of AML(M7). Genes Chromosome Cancer 23:61, 1998